United Therapeutics (UTHR) Misses Q2 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $607.47 +1.02%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9 million versus the consensus estimate of $689.93 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics Corp. (UTHR) PT Raised to $768 at BTIG
- United Therapeutics (UTHR) Misses Q3 EPS by 50c, Beats on Revenue
- The Next 25 Years of Airport Security
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
